Cholecystokinin as a factor in the enhanced potency of spinal morphine following carrageenin inflammation
Open Access
- 1 April 1993
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 108 (4) , 967-973
- https://doi.org/10.1111/j.1476-5381.1993.tb13493.x
Abstract
1 Cholecystokinin (CCK) has been shown to diminish opioid analgesia. Here we investigate whether changes in the physiological levels of spinal CCK are responsible for the enhanced potency of spinal morphine in animals following carrageenin inflammation, as compared with normal animals. 2 Single dorsal horn nociceptive neurones were recorded in intact halothane-anaesthetized rats in the presence and absence of carrageenin-induced inflammation and comparisons were made between the two groups of animals. Inflammation was induced by the injection of 100 μl of 2% λ-carrageenin into the hind paw. 3 The inhibitory effect of intrathecal morphine on the C-fibre-evoked responses of the neurones was enhanced in the carrageenin-treated animals such that the effects of 0.25 μg and 10 μg of morphine in normal animals were comparable to those of 0.01 μg and 2.5 μg in the carrageenin animals. The effect of 0.2 mg kg−1 of the CCKB antagonist, L-365,260, on the antinociceptive potency of intrathecal morphine was examined in both groups of animals. In normal animals, L-365,260 produced a significant enhancement in the effect of morphine indicating a tonic CCK modulation in these animals, but it had no effect on the inhibitions produced by either dose of morphine in the carrageenin animals. 4 The inhibition of the C-fibre-evoked response produced by intrathecal morphine in the presence of 1 μg of CCK was examined in both groups of animals. CCK attenuated the effects of morphine only in animals with carrageenin inflammation, having no effect on the action of morphine in normal animals. 5 The effects of both CCK and L-365,260 were therefore dependent on the inflammatory state of the animal, with each drug being active in opposite situations. 6 We propose that in normal animals, morphine may produce a maximal stimulation of the release of CCK such that exogenous CCK is unable to reduce further the analgesic effects under these conditions. However, the differential effects of the agonist and antagonist in the normal and inflamed rats points to a role of CCK in the enhanced opiate actions. This enhancement of the potency of spinal morphine in inflammation is best explained by a reduction in spinal CCK release by morphine in this state.Keywords
This publication has 38 references indexed in Scilit:
- Activity-dependent neuronal plasticity following tissue injury and inflammationTrends in Neurosciences, 1992
- Cholera toxin and pertussis toxin on opioid- and α2-mediated supraspinal analgesia in miceLife Sciences, 1991
- Recent advances in the physiology and pharmacology of pain: plasticity and its implications for clinical analgesiaJournal of Psychopharmacology, 1991
- Opioids can evoke direct receptor-mediated excitatory effects on sensory neuronsTrends in Pharmacological Sciences, 1990
- In vivo release of CCK‐8 from the dorsal horn of the rat: Inhibition by DAGOLFEBS Letters, 1989
- Antagonism of morphine analgesia by CCK-8-S does not extend to all assays nor all opiate analgesicsPeptides, 1988
- Intrathecal cholecystokinin interacts with morphine but not substance P in modulating the nociceptive flexion reflex in the ratPeptides, 1987
- Minireview: Multiple MU opiate receptorsLife Sciences, 1986
- Actions of Cholecystokinin Octapeptide on Rat Spinal Dorsal Horn NeuronsaAnnals of the New York Academy of Sciences, 1985
- Physiological properties of unmyelinated fiber projection to the spinal cordExperimental Neurology, 1966